Paul Jeng
Stock Analyst at Guggenheim
(2.05)
# 3,304
Out of 4,792 analysts
31
Total ratings
53.8%
Success rate
1.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Maintained: Buy | $10 | $3.31 | +202.11% | 7 | Sep 11, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $54 → $57 | $37.45 | +52.20% | 9 | Sep 9, 2026 | |
| CHRS Coherus Oncology | Reiterated: Buy | $12 → $10 | $1.34 | +646.27% | 2 | Aug 6, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $45 | $8.24 | +446.12% | 2 | Jun 2, 2026 | |
| IMTX Immatics | Reiterated: Buy | $19 | $8.75 | +117.14% | 5 | May 12, 2026 | |
| CNTX Context Therapeutics | Reiterated: Buy | $5 | $0.3664 | +1,264.63% | 4 | May 6, 2026 | |
| IMCR Immunocore Holdings | Initiated Coverage: Hold | n/a | $33.58 | - | 1 | Sep 17, 2025 | |
| TARA Protara Therapeutics | Initiated Coverage: Buy | $50 | $3.79 | n/a | 1 | Jul 29, 2020 |
Adagene
Sep 11, 2026
Maintained: Buy
Price Target: $10
Current: $3.31
Upside: +202.11%
IDEAYA Biosciences
Sep 9, 2026
Reiterated: Buy
Price Target: $54 → $57
Current: $37.45
Upside: +52.20%
Coherus Oncology
Aug 6, 2026
Reiterated: Buy
Price Target: $12 → $10
Current: $1.34
Upside: +646.27%
Corbus Pharmaceuticals Holdings
Jun 2, 2026
Reiterated: Buy
Price Target: $45
Current: $8.24
Upside: +446.12%
Immatics
May 12, 2026
Reiterated: Buy
Price Target: $19
Current: $8.75
Upside: +117.14%
Context Therapeutics
May 6, 2026
Reiterated: Buy
Price Target: $5
Current: $0.3664
Upside: +1,264.63%
Immunocore Holdings
Sep 17, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $33.58
Upside: -
Protara Therapeutics
Jul 29, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $3.79
Upside: n/a